Scarica l'app Stockscreener
11.82
2.64%
-0.32
Dopo l'orario di chiusura:
11.85
0.03
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$12.14
Aprire:
$12.08
Volume 24 ore:
2.50M
Relative Volume:
0.78
Capitalizzazione di mercato:
$2.52B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-8.7556
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
-5.89%
1M Prestazione:
+5.07%
6M Prestazione:
+24.95%
1 anno Prestazione:
+35.24%
Intervallo 1D:
$11.60
$12.19
Intervallo di 1 settimana:
$11.60
$12.66
Portata 52W:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.82 | 2.59B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - Yahoo Finance
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Finviz
Fat Pitch FinancialsOcular Therapeutix, Inc.Common Stock (Nasdaq:OCUL) Stock Quote - FinancialContent
Ocular Therapeutix announces first patient randomized in HELIOS-3 program - MSN
Ocular Therapeutix Earnings Notes - Trefis
Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Trading Systems Reacting to (OCUL) Volatility - Stock Traders Daily
Revenue per share of Ocular Therapeutix Inc – BER:0OT - TradingView — Track All Markets
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt? - 富途牛牛
Aug Action: Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Sentiment Report & High Yield Stock Recommendations - Улправда
What is the fair value of Ocular Therapeutix Inc. stock nowTrade Volume Report & Long Hold Capital Preservation Plans - ulpravda.ru
Can Ocular Therapeutix Inc. stock hit analyst price targetsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock worth buying before Fed action2025 Top Gainers & Verified Short-Term Plans - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Volume Summary: What is the fair value of Ocular Therapeutix Inc. stock now - ulpravda.ru
Can Ocular Therapeutix Inc. (0OT) stock retain market dominanceEarnings Recap Summary & Weekly Stock Performance Updates - DonanımHaber
How Ocular Therapeutix Inc. stock reacts to job market dataWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
What makes Ocular Therapeutix Inc. stock attractive to growth funds2025 Market WrapUp & Real-Time Market Sentiment Reports - DonanımHaber
Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Pullback Review & Community Trade Idea Sharing Platform - Улправда
Is Ocular Therapeutix Inc. stock in correction or buying zoneQuarterly Profit Report & Smart Swing Trading Alerts - Улправда
How Ocular Therapeutix Inc. stock benefits from global expansion2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Ocular Therapeutix Inc. stock reach all time highs in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - ulpravda.ru
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3%What's Next? - MarketBeat
Ocular Therapeutix enters quiet period ahead of SOL-1 milestone - MSN
Assessing Ocular Therapeutix (OCUL) Valuation After Accelerated FDA Filing Plan for AXPAXLI in Wet AMD - Sahm
Ocular Therapeutix stock could see 45% upside if trial succeeds, TD Cowen says - Investing.com Canada
RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating - marketscreener.com
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
Ocular Therapeutix Inc. (OCUL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):